Management of patients with lower-risk myelodysplastic syndromes

1

Myelodysplastic syndromes (MDS) primarily affect the elderly, with lower-risk MDS (LR-MDS) indicating a reduced risk of death or progression to acute myeloid leukemia (AML).
2

Anemia and complications from cytopenias in LR-MDS patients can negatively impact quality of life and increase mortality compared to the general population.
3

Accurate diagnosis of MDS involves a combination of blood smear analysis, bone marrow cytology, cytogenetic testing, and molecular profiling.
4

Recent updates to MDS classification systems emphasize the importance of specific mutations and immunophenotypic alterations in diagnosis and prognosis.
5

Emerging therapies targeting disease pathways in LR-MDS highlight the need for structured assessments of treatment responses and patient-reported outcomes.

1